Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8177567 | 1.00 | DDB1 (0.52) | DDB1CRBNHDAC2MEN1KMT2A | |
| SCHEMBL16796843 | 1.00 | DDB1 (0.52) | DDB1CRBNHDAC2MEN1KMT2A | |
| SCHEMBL10252171 | 0.89 | IKBKB (0.45) | DDB1CRBNHDAC2MEN1KMT2A | |
| SCHEMBL1274980 | 0.88 | DDB1 (0.44) | DDB1CRBNHDAC2SMN1; SMN2PDE4A | |
| SCHEMBL15874659 | 0.86 | DDB1 (0.43) | DDB1CRBNHDAC2PDE4APDE4B | |
| SCHEMBL3237381 | 0.86 | DDB1 (0.43) | DDB1CRBNHDAC2PDE4APDE4B | |
| SCHEMBL8920709 | 0.83 | DDB1 (0.45) | DDB1CRBNHDAC2 | |
| SCHEMBL157619 | 0.80 | BRD4 (0.50) | DDB1CRBNMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6247618 | 0.80 | BRD4 (0.50) | DDB1CRBNMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9295153 | 0.80 | BRD4 (0.50) | DDB1CRBNMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884628-B2 | Method for synthesizing lactam derivatives without use of catalyst | GUIZHOU UNIVERSITY (CN) | 2024-01-30 | — | — | US | claimed |
| EP-4178954-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES AS MEDIATOR OF THE GLUCOCORTOID RECEPTOR | Grünenthal GmbH (DE) | 2023-05-17 | — | — | EP | claimed |
| US-20220177429-A1 | METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST | GUIZHOU UNIVERSITY (CN) | 2022-06-09 | — | — | US | claimed |
| WO-2020228170-A1 | CATALYST-FREE SYNTHESIS METHOD FOR LACTAM DERIVATIVE | 贵州大学 | 2020-11-19 | — | — | WO | claimed |
| CN-109942473-B | Method for synthesizing lactam derivative without catalyst | 贵州大学 | 2020-09-15 | — | — | CN | claimed |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2025217212-A1 | MAC1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| WO-2025106362-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4526300-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-6162417-A | Pyrrolo isoquinolines | EMORY UNIVERSITY (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000027812-A1 | PHENYL-SUBSTITUTED CYCLIC ENAMINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000021958-A1 | 2-HETARYL-3,4-DIHYDRO-2H-PYRROLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999059967-A1 | 2-(2-METHYLPHENYL)-3,4-DIHYDRO-2H-PYRROL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999059968-A1 | 2-(2-CHLOROPHENYL)-3,4-DIHYDRO-2H-PYRROL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-25 | — | — | WO | disclosed |
| EP-0942901-A1 | CYCLIC IMINES AS PESTICIDES | BAYER AG (DE) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022438-A1 | CYCLIC IMINES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-28 | — | — | WO | disclosed |
| US-5401856-A | Carbonylation of allylmethylamine | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 1995-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884628-B2 | Method for synthesizing lactam derivatives without use of catalyst | COASY, SI, NAAA | DDB1 4580/4885CRBN 2638/4885HDAC2 1074/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | DDB1 3633/4885CRBN 546/4885HDAC2 1018/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | DDB1 633/4885CRBN 3079/4885HDAC2 2676/4885 |
| US-20220177429-A1 | METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST | COASY, SI, NAAA | DDB1 4580/4885CRBN 2638/4885HDAC2 1074/4885 |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | DDB1 653/4885CRBN 4377/4885HDAC2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.